uploads/2017/11/Internal-Medicine-1.png

How Has Pfizer’s Internal Medicine Portfolio Performed in 2017?

By

Updated

Lyrica revenue trends

In 3Q17, Pfizer’s (PFE) Lyrica reported revenues of $1.3 billion, which is ~4% growth on a year-over-year (or YoY) basis and 2% growth on a quarter-over-quarter basis. During the first nine months of 2017, Lyrica reported revenues of $3.8 billion, which reflected ~2% growth on a YoY basis. Lyrica generated revenues of $2.6 billion and $1.2 billion, respectively, during the first nine months of 2017 from the US market and international markets, respectively.

In October 2017, the Food and Drug Administration (or FDA) approved Lyrica CR extended-release tablets for the treatment of neuropathic pain related to diabetic peripheral neuropathy and the treatment of postherpetic neuralgia.

Viagra revenue trends

In 3Q17, Viagra generated revenues of $308 million, a ~20% decline on a YoY basis and a 12% decline on a quarter-over-quarter basis. Viagra reported year-to-date September 2017 revenues of $996 million, a ~16% decline on a YoY basis. In the US and international markets, Viagra reported revenues of $687 million and $309 million in the first nine months of 2017, respectively, which is a ~21% and 1% decline on a YoY basis.

Viagra’s competitors include Bayer’s (BAYZF) Staxyn and Levitra and Eli Lilly’s (LLY) Cialis. The Pharmaceuticals ETF (PPH) invests ~5.2% and 4.6% of its total portfolio holdings in Pfizer and Eli Lilly, respectively.

Chantix/Champix revenue trends

In 3Q17, Chantix/Champix generated revenues of $240 million, which is ~21% growth on a YoY basis and a 3% decline on a quarter-over-quarter basis. Chantix/Champix reported revenues for the first nine months of 2017 of $727 million, which is ~15% growth on a YoY basis. In the US and international markets, Chantix/Champix reported revenues of $542 million and $184 million, respectively, in the first nine months of 2017 compared to revenues of $449 million and $182 million in the first nine months of 2016.

Toviaz revenue trends

In 3Q17, Toviaz generated revenues of $62 million, which is ~3% growth on a YoY basis. Pfizer’s Toviaz reported YTD September 2017 revenues of $187 million, which is ~2% growth on a YoY basis. In the US and international markets, Toviaz reported revenues of $63 million and $124 million, respectively, in the first nine months of 2017 compared to $72 million and $119 million in the first nine months of 2016. Toviaz’s competitors include Allergan’s (AGN) Enablex.

BMP2 revenue trends

In 3Q17, BMP2 (Bone Morphogenetic Protein 2) generated revenues of $79 million, which is ~25% growth on a YoY basis and 39% growth on a quarter-over-quarter basis. Pfizer’s BMP2 reported revenues for the first nine months of 2017 of $198 million, a ~13% increase on a YoY basis.

More From Market Realist